Artificial intelligence news.
Straight from the original announcements.

Lunit and Summit Team Up to Study Tumor Microenvironment in Ivonescimab Research

October 24, 2026, 03:26By the AI News Bites Editorial TeamSource: PR Newswire
Lunit and Summit Team Up to Study Tumor Microenvironment in Ivonescimab Research
Image: PR Newswire

Lunit and Summit Therapeutics have signed a research agreement to evaluate Lunit's AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in Summit's immuno-oncology programs with ivonescimab. The work will apply AI to standard stained tissue images to support biomarker discovery and patient selection.

Key points
  • Lunit and Summit Therapeutics signed a research agreement to evaluate Lunit SCOPE IO in ivonescimab immuno-oncology programs.
  • The platform analyzes H&E whole-slide images and, according to Lunit, needs no additional stains or assays.
  • Goals include biomarker discovery, patient stratification or selection, and understanding response to ivonescimab.
  • No clinical outcome data were announced, and SCOPE products are for research use only.
  • Ivonescimab is investigational and not approved in Summit's license territories, including the US and Europe.

What the agreement covers

Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) announced the research agreement from Seoul on Oct. 24, 2026. The effort will apply Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images in order to characterize features of the tumor microenvironment.

According to the companies, the aim is to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Lunit describes SCOPE IO as a platform designed to support immuno-oncology research and biomarker development. It analyzes H&E slides with AI, which, according to the company, allows scalable assessment of tumor microenvironment features without requiring additional stains or assays.

Why tumor microenvironment analysis matters

The release argues that the agreement reflects the growing importance of computational pathology in oncology drug development. Routine H&E slides hold information about tumor architecture, immune infiltration, stromal organization and spatial interactions within the tumor microenvironment. Traditional manual assessment, the companies say, can be difficult to scale and may not fully capture the quantitative and spatial complexity of the tumor-immune interface.

AI-powered analysis, they state, offers the potential to turn these routinely generated pathology images into reproducible, high-dimensional biomarker data.

Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit, said understanding the tumor microenvironment is "increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations." Lunit CEO Brandon Suh said that by extracting quantitative, spatially resolved features from standard H&E slides, the company believes SCOPE IO "can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why."

About ivonescimab

Summit is developing ivonescimab, described as a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. It combines immunotherapy through PD-1 blockade with the anti-angiogenesis effects associated with blocking VEGF in a single molecule. Summit believes its tetravalent structure, with four binding sites, enables higher avidity in the tumor microenvironment.

According to the release, ivonescimab was invented by Akeso Inc. and is used in multiple Phase III clinical trials. There are 17 Phase III studies announced, ongoing or completed, five of them Summit-sponsored global studies. Five Phase III trials have read out so far, all with positive data, according to the release. Ivonescimab was initially approved in China in May 2024, but it is an investigational therapy not approved by any regulatory authority in Summit's license territories, including the United States and Europe.

Limits and what it means

The release is clear about the scope of the work. No clinical outcome data are being announced, and Lunit SCOPE products are for research use only, not for use in diagnostic procedures or decisions.

The companies expect the collaboration to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies and clinical development planning. For the industry, the agreement is one example of a pathology AI developer working with a drug developer to look for biomarkers in routine tissue samples. Whether the approach yields usable biomarkers for ivonescimab remains to be shown by the research itself.

LunitSummit TherapeuticsLunit SCOPE IOivonescimabhealthcareresearch findingspartnerships

Related news

Business
BusinessNovember 19, 2026, 20:27

Isomorphic Labs and MSD Partner on AI-Driven Cancer Drug Discovery

Isomorphic Labs and MSD have agreed to collaborate on discovering small-molecule drug candidates for a strategically important cancer indication. The partnership…

SAS and Posit Partner on Governed AI for Life Sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit Partner on Governed AI for Life Sciences

SAS and Posit PBC have formed a partnership to give life sciences organizations more flexibility in using SAS and open-source technologies, initially for clinical…

SAS and Posit partner to bring governed open source AI to life sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit partner to bring governed open source AI to life sciences

SAS and Posit PBC are partnering to give life sciences organizations more flexibility to use SAS and open source technologies in regulated clinical development. The…